“Bimekizumab Efficacy and Safety through Two Years in Patients With Moderate Psoriasis: Analysis of Pooled Data from Five Phase 3 3b Clinical Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s67, https://doi.org/10.25251/skin.6.supp.67.